Explore the Agenda

8.00am – 9:00am One-on-One Partnering™ Portal Opens for Private Morning Meetings

9:00 am Day Two Chair’s Opening Remarks

Translating Preclinical Optimism to Clinical Success Across TPD Expanding the E3 Ligase Target Universe & Leveraging PROTACs with Antibodies

9:10 am The Next Generation of Validated Protein Degradation

Translational Medicines Associate Director, AnHorn Medicines
Chief Business Officer & General Manager (US), Polymed Biopharmaceuticals
CEO, Proxima Bio
Founder & Chief Executive Officer, Pin Therapeutics
  • Optimizing physical chemical properties for more favourable ADME characteristics of TACs
  • Leveraging PROTACs as binders for antibodies, as well as payloads
  • Discussing rationally designing candidates that break out of the structural constraints of E3 ligases

9:30 am Showcase Your Science: Attending Companies’ Opportunity to Present

Present your company’s slides by securing a 15 minute presentation slot in front of the attending audience.

What is this session?

Following the same structure as the two presentation sessions on conference day one,

these are further presentation slots, so pharma has more opportunity to listen to pitches

from leading biotech across Asia. Whether you are seeking to increase interest specifically

with big pharma, or didn’t manage enough exposure at JPM or BIO conferences, this is a

more targeted opportunity to share your company profile with key buyers.

How does this session work?

Add a presentation slot to your registration through the website or by getting in touch, so you can generate interest in your assets ahead of the drinks reception.Once secured, submit your talk title and brief synopsis to us, as well as your dedicated speaker and we will update this brochure to advertize your talk.

Who can present?

We are excited to host innovative science across Asia. Whether you are working on DCs, BsABs, TCEs, TPD or RLTs, your senior scientific team would be a valued addition to this program

Presentation Session Full

9.30 Presentation by Ubix Therapeutics

9.45 Presentation by Pin Therapeutics

10.00 Presentation by Chordia Therapeutics

10.15-10.45 Presentations available

10:45 am Morning Break & Networking Opportunity

11:00 am One-on-One Partnering™ Portal Opens for Private Meetings

Individual Meetings: One-on-One PartneringTM

To maximize your opportunity to secure key connections before the conference ends, meet with pharma and bitoech connections in one-to-one meeting arranged through the partnering system

12:00 pm Lunch Break & Networking Opportunity

1:00 pm Showcase Your Science: Attending Companies’ Opportunity to Present

Present your company’s slides by securing a 15 minute presentation slot in front of the attending audience.

What is this session?

So as to host as many exciting pipeline updates and introductions to exciting new companies as possible, this is an additional session with presentation sessions available to those attending. Make sure you don’t leave the conference without getting to pitch your technologies for out-licensing or co-development to those with decision-making power, prioritizing access to Asia assets.

1.00 Presentation by CELLemedy

1.15-2.15 Presentations available

2.15 Presentation by Velavigo

2:30 pm Afternoon Break & Networking Opportunity

Advancing Best- & First-in-Class Across ADCs & RLTs: Improving Through More Selective Targeting

3:10 pm Competing in a Crowded ADC Landscape: What Does True Clinical Differentiation Look Like in Today’s ADC Market?

Chief Executive Officer, Bliss Bio
CEO, Portrai
Executive Director Scientist), Oncology Clinical Research, Early Development, Merck
Founder & Chief Executive Officer, VelaVigo
  • How can we improve toxicity profiles and delivery better than Enhertu?
  • What and how are leaders achieving efficacy beyond a monospecific with a BsAb and BsADCs
  • Leveraging synergy between biology of targets and binding events to improve ADC performance

3:30 pm Aligning Target Biology, Binder Format & Isotope with Tumor Treatment Paradigm

Chief Executive Officer, RadioPharm Theranostics
Co-Founder, Nurix Therapeutics
  • Discussing different pharmacokinetic properties of binders, including small molecule, peptide, mAbs and nanoparticles
  • Evaluating need, niche, and efficacy when matching target biology to binder format and isotope
  • Leveraging imaging to derisk and prove safety to curate a faster path to clinical proof of concept
  • How do considerations around isotopes play into deal-making?

3:50 pm Chair’s Closing Remarks

4:00 pm End of Conference